According to the Bureau of Prisons' projected release date, disgraced former Theranos Chief Executive Elizabeth Holmes may be released from prison two years sooner than anticipated.
Holmes was sentenced to 11-years and 3-months in prison by the end of 2012, but she reported to a Texas camp in May. According to the Bureau of Prisons' online database, Holmes is expected to be released on December 29, 2032, which would mean that she will have served about two years of her sentence.
The difference appears to be caused by the way in which the Bureau of Prisons estimates its estimated release date.
According to a spokesperson from the Bureau of Prisons, CNN, the agency is unable to comment on individual inmates' conditions. However inmates are able earn Good Conduct Time or GCT that will be calculated into their projected date of release. Inmates who meet the qualifications can earn up to 54 GCT days for every year they are sentenced by a court.
The spokesperson pointed out that inmates can earn time credits in prison by participating in different programs. The factors used to calculate an estimated release date do not apply only to Holmes, but are standard for all inmates.
Holmes is currently serving her sentence in Federal Prison Camp Bryan. This is a federal minimum security prison camp located approximately 100 miles away from Houston. In May, an appeals court denied her request to be released on bail as she fought to overturn the conviction.
Holmes was once a tech icon, a poster girl for Silicon Valley's limitless potential and ambitions. She is one of only a few tech executives who are currently serving prison time. She was convicted in early 2017 on multiple counts of defrauding Investors while running Theranos.
Theranos reached a peak valuation of $9 billion, making Holmes a "paper billionaire". The company started to crumble after a Wall Street Journal report in 2015 revealed that Theranos only performed a dozen out of hundreds of tests using its proprietary technology and had a questionable accuracy. Theranos also revealed that it relied on devices manufactured by traditional blood-testing companies, rather than its proprietary technology.